Breaking News

Independent Study Demonstrates 97 Per cent of Vivos Clients Reached Their Preferred Treatment Consequence

HIGHLANDS RANCH, Colo., July 07, 2021 (Globe NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a health-related technologies corporation targeted on acquiring and commercializing impressive diagnostic and procedure modalities for sufferers suffering from sleep-disordered breathing, such as moderate-to-moderate obstructive slumber apnea (OSA), today declared that the Enterprise has unveiled new info from an impartial client survey connected to its proprietary Vivos procedure for treating dental tissue anomalies and dentofacial malformations known to be affiliated with OSA and other debilitating health problems.

Essential findings involve:

  • Just about all (97 %) of individuals surveyed reported that they experienced realized their wanted final result from the Vivos procedure for their OSA.

  • About 50 % (63 per cent) of people surveyed explained that they depend on the tips of their dentist to come across a long lasting alternative that addresses the root result in of their OSA.

  • Almost just one-3rd (29 %) of people surveyed explained that they searched for non-surgical alternate options to existing criteria of treatment for dealing with OSA.

“Patients are the greatest arbiter of no matter if a particular treatment method modality has realized its sought after effects,” mentioned Kirk Huntsman, Vivos Chairman and CEO. “This survey reaffirms that sufferers are in dire have to have of a answer for their OSA – one that is non-surgical, non-invasive, non-pharmaceutical and very low-charge – and which is just the industry area of interest that the Vivos procedure fills. The actuality that almost all people surveyed claimed that they experienced accomplished their preferred cure outcome is a highly effective testimony about their clinical and beauty success. Our engineering just performs.”

The sought after final result for lots of Vivos clients is usually a major reduction in OSA and associated signs and symptoms, as affected individual pleasure and compliance costs with CPAP keep on being dismal. Some scientific studies demonstrate only 30 to 60 % CPAP adherence, and when still left untreated OSA’s underlying ailments can turn into continual comorbidities, some of which may perhaps be life threatening. In distinction, the Vivos remedy is generally accomplished in about 12 to 24 months, just after which most people no for a longer time demand ongoing intervention.

Methodology:
Commissioned by Vivos, The EyeDeas Organization, an impartial analysis corporation, made the study and analyzed the knowledge received from 123 anonymous individuals from 21 unbiased Vivos-experienced clinicians residing in several markets in the U.S., in regards to the use and benefits of the Vivos cure for addressing dental tissue anomalies and dentofacial malformations. Fieldwork was carried out in June, 2021.

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technological innovation corporation focused on developing and commercializing progressive diagnostic and procedure modalities for grownup patients struggling from snooze-disordered respiratory, which include obstructive sleep apnea (OSA). The Vivos cure for moderate-to-average OSA includes a custom-made oral appliance and protocols referred to as the Vivos Technique. Vivos thinks that its Vivos Technique oral appliance technologies represents the very first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-efficient solution for people with gentle-to-reasonable OSA. Vivos also sells orthodontic appliances for older people and little ones. Vivos’ oral appliances have tested efficient in in excess of 17,000 patients around the world by a lot more than 1,200 dentists. Combining technologies and protocols that change the dimension, shape, and place of the tissues of a patient’s higher airway, the Vivos Technique opens airway place and could significantly lessen indications and situations connected with moderate-to-moderate OSA, this kind of as lowering Apnea Hypopnea Index scores. Vivos also marketplaces and distributes VivosScore, run by the SleepImage diagnostic technology for Dwelling Slumber Screening in grownups and young children. The Vivos Built-in Follow (VIP) program presents dentists education and other price-additional providers in connection with making use of the Vivos Program.

For extra information and facts, check out www.vivoslife.com.

Cautionary Notice Regarding Ahead-Seeking Statements
This press release and statements of the Company’s administration manufactured in connection therewith have “forward-seeking statements” (as outlined in Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Exchange Act of 1934, as amended) regarding foreseeable future functions, notably with respect to the public offering explained herein. Text these kinds of as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and versions of such terms and identical expressions are intended to recognize ahead-seeking statements. These statements entail known and unknown dangers and are centered on various assumptions and estimates, which are inherently matter to considerable uncertainties and contingencies, quite a few of which are beyond Vivos’ manage. Actual effects (such as the expected rewards of the Company’s engineering as explained herein) could vary materially from those expressed or implied by these types of ahead-seeking statements. Variables that could trigger precise results to vary materially incorporate, but are not constrained to, the threat variables explained in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be attained no cost of charge on the SEC’s web site at www.sec.gov. Besides to the extent essential by regulation, Vivos expressly disclaims any obligations or endeavor to launch publicly any updates or revisions to any forward-hunting statements contained herein to reflect any adjust in Vivos’ expectations with regard thereto or any alter in functions, situations, or circumstances on which any statement is based mostly.

Investor Relations Get in touch with:
Edward Loew
Trader Relations Officer
(602) 903-0095
ed@vivoslife.com

Media Relations Make contact with:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (212) 896-1231
ckasunich@kcsa.com / jrobles@kcsa.com